Evidence & regulatory context
- Mechanism
- Recombinant annexin A6; no ChEMBL entity (protein). No ClinicalTrials.gov record for annexin A6; the 64 annexin hits were 99mTc-HYNIC-annexin A5 apoptosis imaging and unrelated studies, excluded as a different protein used diagnostically rather than therapeutically.
- Target
- Not recorded
- Injury models
- Other
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseOther
Model: Acute skeletal muscle plasma membrane injury in vitro and in vivo, plus a mouse model of muscular dystrophy
Recombinant annexin A6 reduced membrane injury and protected against acute muscle injury in vitro and in vivo, and lowered serum creatine kinase in a muscular dystrophy model, consistent with enhanced membrane repair.
Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.
